Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shortfalls in the drug's label, leaving more to be desired—and ...

As previously reported, the LYNX-1 Phase 3 study met its primary endpoint, with a statistically significant greater percentage of Phentolamine Ophthalmic Solution 0.75%-treated participants gaining 15 ...

Esperion Therapeutics ESPR announced that it has come to an alignment with the FDA for initiating two phase III studies. The ...

The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...